COVID-19 Funding Opportunities

COVID-19 Research Grants for Combating the coronavirus crisis

Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.

As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.

Expand/Collapse All
Biomedical Advanced Research and Development Authority (BARDA)

BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat.  BARDA’s annual budget of $512 Million has been supplemented by an additional $3.5 billion through the recently passed Coronavirus Aid, Relief, and Economic Security (CARES) Act.  The additional funding is allocated for necessary expenses of manufacturing, production, and purchase of various supplies and services.

BARDA BAA

View Solicitation

Topic: Products to diagnose, prevent or treat novel coronavirus infections
Due Date: Rolling, through 10/31/2020
Budget: Unlimited


Division of Research, Innovation & Ventures (DRIVe) BAA DEADLINE APPROACHING

View Solicitation

Topics: Diagnostic assays, screening and model development, vaccines, advanced manufacturing.

Due Date: Abstract submissions due by 5PM ET on 10/31/2020.
Budget: $750,000


CoronaWatch

While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel.  A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.

Request CoronaWatch Meeting


National Institutes of Health (NIH) NEW! DEADLINE APPROACHING
NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)

View Solicitation

Description: The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies with the potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. No preliminary data are required.

Topics: Any area of research relevant to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics

Due Dates: 9/30/2020 (opens 8/30/2020)
Budget: Not limited, but must be commensurate with the scope of the proposed research



NIA Multi-site COVID-19 Related Clinical Trial
NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) NEW!

Description: The National Institute on Aging (NIA) invites applications for the implementation of investigator-initiated multi-site clinical trials (at all phases or stages) of interventions focused on specific aging-related issues and aimed at reducing the transmission, risk, morbidity, mortality, severity, or complications of COVID-19.

Topics:

  • Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults
  • Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection
  • Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers
  • Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer’s disease or Alzheimer’s disease-related dementias (AD/ADRD), or underlying comorbidities
  • Trials in at-risk older adults aged 65 and older for whom electronic medical records are available and long-term outcomes can be tracked and in institutions serving those populations
  • Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g., incarcerated, homeless, living in institutions)

Due Dates: 10/1/2020, 11/2/2020, 12/1/2020, 1/4/2021, and 2/1/2021
Budget: Not Limited



R01 Grants for Community Interventions
Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)

Description: The National Institutes of Health has announced an R01 funding opportunity encouraging applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.

Topics:

  • Research topics of interest relate to the behavioral, social, socioeconomic and health impacts of the COVID-19 pandemic with respect to health disparity and vulnerable populations. See the solicitation for a list of example topics.

Due Dates: 12/1/2020
Budget: $500,000 in direct costs


Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional)>

Description: The NIH has announced a funding opportunity focusing on the role and impact of digital health interventions, (e.g., mobile health [mhealth], telemedicine and telehealth, health information technology [IT], and wearable devices) to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the COVID-19 pandemic, particularly in populations that experience health disparities and vulnerable populations.

Topics: See the solicitation for a detailed description of relevant topics and high-priority study areas

Due Dates: 12/2/2020 and 3/2/2021
Budget: $750,000 in direct cost per year for up to 3 years


Notices of Special Interest (NOSI) NEW!

Multiple NIH Institutes have issued Notices of Special Interest (NOSIs) to provide funding for research topics related to COVID-19.  For most of these opportunities, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NEW!
Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract

Description: The NICHD invites applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Proposals should be submitted to either PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) or PA-18-482 NICHD Exploratory/Developmental Research Grant (R21 – Clinical Trial Optional).

Topics: Areas of interest of this NOSI include, but are not limited to:

  • Consequences of infection, e.g., cells affected and outcomes of infection – infertility, miscarriage, live births, orchitis, epididymitis, pelvic pain;
  • Mechanism of action for infectivity of reproductive tract tissues;
  • Whether the reproductive tract acts as a reservoir for viruses;
  • Sex-specific differences in infection as they may relate to reproductive tract tissues and cells;
  • The impact of race and ethnicity on reproductive system impacts of viruses;
  • Impact of nutrition, e.g., Vitamin D sufficiency and the understanding of mechanisms that explain the impact of obesity;
  • Development of model systems to study infections in reproductive tract tissues, e.g., organoids (for R21 applications only)

Due Dates: Standard R01 due dates apply. This NOSI expires on 5/8/2023 .
Budget: Not limited


Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities
View solicitation

Description: The NIH has released a Notice of Special Interest to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities, including those related to COVID-19. Proposals should be submitted using the funding opportunity announcement “PA-20-185 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).”

Topics: The specific areas of interest of each participating institute or center are listed in the NOSI (see link), but in general, proposals are solicited for projects addressing the following research objectives:

  • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using simulation modeling and systems science (SMSS)
  • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
  • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
  • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
  • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
  • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities

Due Dates: Standard R01 due dates apply. This NOSI expires on 5/8/2023 .
Budget: Not limited


Multi-Institute NOSI: Community Interventions
NOSI: Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations

Description: The NIH has released a Notice of Special Interest for competitive and administrative supplements to test community interventions focused on preventing (or slowing) COVID-19 transmission, evaluate local and state policies and programs intended to mitigate COVID-19 exposure and improve adherence, and reduce the negative impact of the multifaceted consequences on the health of populations that experience health disparities and other vulnerable groups.

Topics:

  • Mitigation strategies in populations who experience health disparities and other vulnerable groups
  • Evaluating community interventions (existing, new, or adapted) to ameliorate the negative health impacts of the COVID-19 pandemic in populations with health disparities and other vulnerable populations

Due Dates: Applications are accepted on a rolling basis until 12/15/2020.
Budget: $250,000 in direct costs


Multi-Institute NOSI: Digital Interventions
NOSI: Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

Description: The NIH has released a Notice of Special Interest highlighting its interest in research to strengthen the healthcare response to COVID-19 and to future public health emergencies, including pandemics. While research on the direct clinical effects of COVID-19 is supported by other funding opportunities, the purpose of this NOSI is to support research to address the secondary health effects of social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact. Support will be provided through administrative supplements and competitive revisions to existing grants.

Topics:

  • Strategies to increase the reach, access, engagement, efficiency, quality and sustainability of existing evidence-based or validated digital health interventions to address healthcare needs of health disparate and other vulnerable populations, including screening, prevention, self-management, wellness behaviors and treatment both during and following the pandemic
  • Studies to evaluate the near-term impact of replacement (or substitution) of face to face services with digital health as a result of the pandemic to address health disparities and vulnerable population needs

Due Dates: Applications are accepted on a rolling basis until 12/15/2020.
Budget: $200,000 in direct costs


Multi-Institute NOSI: COVID-19 and Down Syndrome

National Institutes of Health

No Current opportunites


NIA/NIMH
NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  • PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements for NIH grantees applying to expand the scope of their active grant.
  • PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

Topics:  NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.

Due Date: Rolling until 5/1/2021
Budget: Limited to no more than that amount of the current parent award.


National Heart, Lung, Blood Institute (NHLBI)
NOSI: Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials

Description: NHLBI is issuing this Notice of Special Interest due to the urgent need for early phase clinical trials to evaluate new or existing interventions that may prevent or treat COVID-19. NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19.

Topics: Safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases

Due Dates: 10/5/2020
Budget: Not specified


NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Topic: COVID-19 related research including host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

Due Date: Rolling, through 10/5/2020
Budget: Not specified


National Institute of Allergy and Infectious Diseases (NIAID)
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

View solicitation

Description: The National Institute of Allergy and Infectious Diseases has issued a Notice of Special Interest encouraging cooperative agreement applications for the implementation of investigator-initiated, high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2. Proposals should be submitted using the funding opportunity announcement “PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).”

Topics: Proposals are sought to evaluate SARS-CoV-2 candidate vaccines, non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19, and therapeutic approaches to treat COVID-19. Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative

Due Dates: Applications will be accepted once a month from 09/14/2020 through 09/14/2021
Budget: Not limited


Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

R21 (Clinical Trial Not Allowed)
R01 (Clinical Trial Not Allowed)

Description: NIAID has announced an expedited funding mechanism for research on SARS-CoV-2 and/or COVID-19.

Topics:

  • Studies to understand critical aspects of viral transmission, infection, replication and pathogenesis
  • Identification and characterization of the onset and duration of immunity in healthy and at-risk populations
  • Virologic and serologic surveillance studies and natural history studies to understand the origin of the virus including the animal host reservoir, potential intermediate hosts, factors leading to spill over events, evidence of continued spill over events and studies at the human-animal interface
  • Studies to assess and characterize the natural history and long-term consequences of SARS-CoV-2 infection in various human populations including at risk populations
  • Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results
  • Development and testing of SARS-CoV-2 therapeutic candidates in relevant in vitroex vivo or animal models
  • Development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates
  • Studies to inform the development of vaccination strategies for at-risk populations including use of age-specific adjuvants or novel antigen formulations/dosing
  • Development of assays and animal models to evaluate the potential of enhanced disease after vaccination for SARS-CoV-2
  • Assess animal models for SARS-CoV-2 and how the models compare to human infection including animal models that represent at risk populations (elderly, immunocompromised, very young, pregnant models)
  • Development of animal models for transmission experiments;
  • Development of organoid culture models and/or ex vivo explant models
  • Computational modeling studies to identify and evaluate interventions to protect at-risk populations and for making public health policy decisions for control and mitigation measures
  • Study interactions and impact between SARS-CoV-2 and other respiratory pathogens including influenza (e.g., co-infections, interference)
  • Comparative studies of SARS-CoV-2 to other coronaviruses including SARS-CoV-1 and MERS
  • Data science approaches to develop algorithms, models, and informatics solutions

Due Dates: Accepting applications on a rolling basis until 4/30/2021
Budget: $275,000 in direct costs for R21; No specified limit for R01


NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Topics: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Due Date: Rolling until 3/25/2021
Budget: Not Specified


Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)

Description: The National Institute of Allergy and Infectious Diseases (NIAID) has released a new funding opportunity to provide personal protective equipment to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 and the Coronavirus Aid, Relief and Economic Security (CARES) Act.

Topics: Purchase of personal protective equipment for use in COVID-19 clinical trials or clinical studies

Due Date:  Applications are accepted on a rolling basis
Budget: Not limited


National Institute of General Medical Sciences (NIGMS)
NOSI: Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Topics: Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).

Due Date: Rolling, through 2/6/2021
Budget: Not Specified


National Center for Advancing Translational Sciences (NCATS) DEADLINE APPROACHING

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

Description: The National Center for Advancing Translational Sciences has released an urgent U01 funding opportunity announcement to invite applications to repurpose existing therapeutic agents to treat COVID-19 sequelae and associated complications that result from SARS-CoV-2 infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Topics: Clinical trials of existing therapeutic agents for treating COVID-19

Due Dates: Applications are accepted on a rolling basis until 1/24/2020.
Budget: $3,000,000 in direct costs per year for up to 3 years


Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Health Need

The National Center for Advancing Translational Sciences (NCATS) has issued a Notice of Special Interest to solicit applications for Administrative Supplements from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients to address COVID-19.

Topics: See the funding opportunity announcement for details of the topics that are specific to UL1 and U24 awards.

Due Dates: Applications are accepted on a rolling basis through 11/10/2020.
Budget: Not specified


NOSI: Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

The NCATS is seeking proposals for emergency administrative supplements and competitive revisions to existing UL1 and U24 CTSA Program awards to address COVID-19 public health needs

Topics:

  • Digital health platforms
  • Planning of COVID-19 trials
  • eConsent support
  • Platforms for meta-analysis of COVID-19 trials
  • Clinical data provision
  • Clinical studies and trials of COVID-19 interventions
  • Assessment of infectious or convalescent status

Due Dates: Applications will be reviewed on a rolling basis through 11/10/2020
Budget: Not specified, but may exceed the current amount of the parent award


NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Due Dates: 11/2/2020
Budget: Application budgets are limited to no more than the amount of the current parent award and must reflect the actual needs of the proposed project.

PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

Due Dates: 11/9/2020, 3/8/2021, 7/9/2021
Budget: $400,000 – $750,000

PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Due Dates: 11/9/2020, 3/8/2021, 7/9/2021
Budget: $275,000 (direct costs)

PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional). DEADLINE APPROACHING

Due date: 9/25/2020
Budget: $750,000/year in direct costs excluding consortium/contractual F&A costs.


PA-18-462 – Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)

Due Dates: 10/16/2020
Budget: $225,000 (direct costs)

PAR-18-332 – Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)

Due Dates: 10/5/2020
Budget: $3,000,000 in direct costs per year.


NOSI: Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

Topic: Use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Due Date: Rolling through 01/26/2022
Budget: 25% total costs of current parent award


National Institute of Drug Abuse (NIDA)
NOSI: Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Topic: NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Due Date: Rolling, through 3/31/2021
Budget: Maximum of $100,000 direct costs per year for 2 years.  Higher budgets may be considered with justification.


National Institute on Deafness and Other Communication Disorders (NIDCD)
NOSI: NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Description: NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech, and language.

Topics: Topics include, but are not limited to, the following:

  • The effects of prolonged oral intubation on laryngeal function and voice production
  • Short-term and long-term effects of COVID-19 on the auditory, vestibular, or olfactory systems
  • The prevalence, onset, and resolution of acquired deficits (i.e., HBTSVSL) among patients with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions
  • The molecular mechanisms underlying chemosensory dysfunction due to SARS-CoV-2 infection
  • The impact of stress/isolation on speech, language or fluency recovery/development in children or adults
  • The impact of potential congenital transmission of maternal SARS-CoV-2 infection to the newborn in relation to the auditory, vestibular, olfactory, or vocal function and/or the impact on speech production or language acquisition
  • Potential ototoxicity from therapeutics or vaccination related to COVID-19
  • Worsening of communicative function because of physical distancing, sheltering in place, and wearing of protective personal equipment during mitigation of this infectious pandemic
  • Telehealth service delivery to individuals with communication disorders
  • Multidisciplinary collaborative teams including clinicians, basic biologists, geneticists, quantitative scientist, epidemiologists, or other researchers to study COVID-19 related human conditions and behaviors, bioethical considerations, health-service delivery, health services in low-resource areas, and health disparities within NIDCD mission areas

Due Dates: Various program-specific due dates on or after 10/5/2020
Budget: Varies by program


National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)

Description: The National Institute of Diabetes and Digestive and Kidney Diseases has announced an R01 funding opportunity to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases. Small businesses and other for-profit organizations are eligible to apply

Topics: Please see the funding opportunity announcement for an extensive list of suggested topics.

Due Dates: 12/16/2020
Budget: $250,000 in direct costs per year for up to 3 years


National Institute of Biomedical Imaging and Bioengineering (NIBIB)

NIBIB has issued a shared set of topics and three separate NOSIs for current grantees, SBIR/STTR applicants, and all other applicants:

Current Grantees NOSI
SBIR/STTR Applicants NOSI
All Other Applicants NOSI

Topics: Rapid diagnostics, wearable/implantable sensors, digital health platforms, healthcare training platforms, robotic technologies to limit caregiver exposure, ventilators, and disinfectant technologies

Due Date: Varies by NOSI
Budget: Varies by NOSI


Rapid Acceleration of Diagnostics (RADx)

Description: NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to  clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including, commercialization and product distribution. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches.

Topics: SARS-CoV-2 diagnostic testing technologies in two stages:

  • Early stage: transformative innovations based on novel testing strategies that have potential for major scale up
  • Advanced stage: modification and optimization of existing SARS-CoV-2 testing approaches, including clinical laboratory tests, that can dramatically increase testing capacity

Due Dates: Rolling
Budget: Not specified


National Institute of Neurological Disorders and Stroke (NINDS)
NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Description: NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Topics: Biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus

Due Dates: Applications accepted on a rolling basis until 4/14/2021
Budget: $200,000 in direct costs


Office of Strategic Coordination (OSC) No current opportunties
National Library of Medicine (NLM)

No current opportunities


National Institute of Dental and Craniofacial Research (NIDCR)
NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR

Description: The National Institute of Dental and Craniofacial Research (NIDCR) has issued a Notice of Special Interest to highlight the urgent need for research on COVID-19 and will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices.

Topics:

  • Prevention of SARS-COV-2 transmission
  • Improvements in the detection and diagnosis of COVID-19
  • Acquisition of a more robust understanding of SARS-CoV-2 pathogenesis
  • Influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity in relation to COVID-19
  • COVID-19 risk, prevention, and health outcomes

Due Dates: 11/2/2020
Budget: $150,000 in total direct costs


National Center for Complementary and Integrative Health (NCCIH)

No current opportunites


NIH Office of the Director

Currently no opportunities available


National Cancer Institute

No current opportunities


RADx-UP

No current opportunities


Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed) DEADLINE APPROACHING

Description: The NIH has released a U24 funding opportunity announcement to fund a single cooperative agreement for a RADx-rad Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The RADx-rad Data Coordination Center (DCC) will provide overarching support and guidance to RADx-rad awardees in the following three areas: (1) Administrative Operations and Logistics, (2) Data Collection, Integration and Sharing, and (3) Data Management and Use.

Topics: Proposals are sought to establish the RADx-rad Data Coordination Center (DCC), which will provide overarching support and guidance to RADx-rad awardees in the following three areas: (1) Administrative Operations and Logistics, (2) Data Collection, Integration and Sharing, and (3) Data Management and Use.

Due Dates: Application due 9/30/2020
Budget: $4 million in annual direct costs for up to 4 years


Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) DEADLINE APPROACHING

Description: This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time.

Topics: Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses.

Due Dates: Applications due 9/30/2020
Budget: Not limited


Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional) DEADLINE APPROACHING

Description: The NIH has announced a new RADx R61/R33 funding opportunity to support innovative research to develop novel approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2-associated illness, including multisystem inflammatory syndrome in children (MIS-C), and predict the longitudinal risk of disease severity (through a prognostic algorithm) after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.

Topics:

  1. Rapid diagnosis and characterization of the spectrum of MIS-C associated with SARS-CoV-2
  2. Accurate risk-stratification and prediction of severe disease (MIS-C) outcomes along the spectrum of SARS-CoV-2 exposure and/or infection and throughout the course of illness

Due Dates: Application due 9/30/2020
Budget: $500,000 in direct costs per year in the R61 phase and $1,000,000 in direct costs per year in the R33 phase


Frederick National Laboratories

No current opportunities

National Science Foundation (NSF)
Dear Colleague Letter on the Coronavirus

View Letter

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

View Letter

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

Department of Defense (DOD) NEW!
Department of the Air Force NEW!

X20.3 SBIR/X20.C STTR Commercial Solutions Opening (CSO) AF Ventures Topics NEW!

View Solicitation for SBIR

View Solicitation for STTR

Description: The US Air Force has issued the pre-release of the latest topics in its SBIR and STTR Commercial Solutions Opening program, which includes a list of Technology Areas of interest to the Air Force. These areas include COVID-19-related technology solutions.

Topics:

  • COVID-19 pandemic materials and manufacturing advances
  • COVID-19 pandemic human performance and medical response advances/solutions
  • COVID-19 pandemic information sciences’ advances/solutions

Due Dates: 10/22/2020
Budget: $150,000


Defense Logistics Agency

No current opportunities


US Department of Agriculture (USDA)
National Institute of Food and Agriculture (NIFA)

In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.

Agriculture and Food Research Initiative (AFRI)

View Solicitation

Topics: Focus areas of interest include, but are not limited to the following:

  • Animal Nutrition, Growth and Lactation (A1231)
  • Critical Agricultural Research and Extension (CARE) (A1701)
  • Diseases of Agricultural Animals (A1221)
  • Food Safety and Defense (A1332)
  • Foundational Knowledge of Plant Products (A1103)
  • Economics, Markets, and Trade (A1641)

Due Date: Varies by Program
Budget: $1,000,000

Distance Learning and Telemedicine (DLT) Grants

No current opportunities

Department of Homeland Security NEW!

Emerging Needs: COVID-19 Response and Future Mitigation NEW!

Description: The Department of Homeland Security is seeking proposals for the Silicon Valley Innovation Program (SVIP) that address the Department’s operational needs in relation to the impact of the coronavirus pandemic. This SVIP Emerging Needs Topic Call seeks technical capabilities that could serve the mission needs of one or more DHS Operational Components and Programs including the DHS Chief Security Officer, DHS Policy, National Biosurveillance Integration Center, Transportation Security Administration, U.S. Citizenship and Immigration Services, and U.S. Secret Service.

Topics: The following illustrative scenarios/use cases are intended to describe where the technologies being sought by DHS in this topic call could potentially be applied:

  • Test and Validation Service for Security & Privacy of Contact Tracing Apps
  • Video Analytics for Self-Screening at TSA Checkpoints
  • Methods to Rapidly Disinfect Surfaces at TSA Checkpoints and other DHS Facilities
  • Collection and Integration of Authoritative Quantitative Open-Source Information
  • Stand-Off Methods for Point of Care Entry Detection at DHS Facilities

Due Dates: 9/30/20
Budget: $50,000 – $200,000


Other US Funding Sources
Schmidt Futures

The Futures Forum on Learning: Tools Competition

Description: The Futures Forum on Learning: Tools Competition (“Tools Competition”) invites teachers, students, researchers, technologists, and ed tech leaders to propose a tool, technology, platform, or research project that can accelerate recovery from COVID-19-related learning loss for students between grades K-12, and advance the field of learning engineering.

Topics: Solutions should aim to address one of the problem areas:

  • Increase the number of students who are reading by 3rd grade
  • Increase the number of students on track in middle-school math
  • Expand the number of students gaining data and computer science skills in high school
  • Driving more students into college through academic and nonacademic supports
  • Another pressing learning goal identified by the team that is related to COVID-19

Due Dates: detailed proposal due 10/26/2020
Budget: Applicants will request an award on one of three tracks: $25,000 and under, $25,000-$100,000, and $100,000-$250,000


XPRIZE Foundation

No current opportunities


Pennsylvania Department of Community and Economic Development

No current opportunities


Wellcome, Bill & Melinda Gates Foundation, and Mastercard

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

View Announcement

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

Due Date: Not Specified
Budget: Not Specified; Total Program Budget – $125,000,000


National Institute of Standards and Technology (NIST)

NIST Manufacturing USA National Emergency Assistance Program

NIST invites applications from the 2,000 current Manufacturing USA institutes, including small manufacturers, two-thirds of Fortune 50 U.S. manufacturers, and nearly every top ranked research and engineering university in the United States.

View Solicitation

Topic: Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

Due Date: Rolling
Budget: $250,000 – $10 million


Coalition for Epidemic Preparedness Innovation (CEPI)

Achieving an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19

Description: CEPI has opened an additional funding opportunity for the rapid development of vaccines against COVID-19, with a goal of achieving licensure/emergency authorization in 12-18 months or less and ensuring the availability of sufficient doses for widespread global deployment as soon as possible in 2021.

Topics: Development of a COVID-19 vaccine for large-scale production

Due Dates: Applications accepted on a rolling basis until at least 6/30/2020
Budget: Not specified


Massachusetts Institute of Technology (MIT)

No current opportunities


California Institute for Regenerative Medicine

Special Call for COVID-19 Projects – Partnership Opportunities in Support of Discovery, Translational and Clinical Trial Stage Activities

View Solicitation

Description: Focusing on the development of therapies for COVID-19, CIRM has issued a special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance new treatments.

Topics:

  • Cell-based COVID-19 therapies that use, target, or are manufactured using stem or progenitor cells
  • Gene therapies for COVID-19 that are intended to replace, regenerate, or repair the function of aged, diseased, damaged, or defective cells, tissues, and/or organs

Due Date: Biweekly on an ongoing basis
Budget: $150,000 – $750,000 depending upon product stage


Amazon Web Services (AWS) Diagnostic Development Initiative (DDI)

No current opportunities


Fast Grants

Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

View Solicitation

Topics: All COVID-19 related science

Due Date: Rolling, award decisions made in 48 hours.
Budget: $10,000 – $500,000


Patient-Centered Outcomes Research Institute (PCORI)

PCORI is requesting enhancements to existing Research Projects and Engagement Awards.

COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects

COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Topics: Modest additions to existing aims as they relate to COVID-19 or new aims designed to produce useful knowledge related to COVID-19 and the original award.  Taking advantage of natural experiments in health system, state, and provider responses is strongly encouraged.

Due Date: Rolling submissions
Budget: $500,000 for Research Projects; $150,000 for Engagement Awards


Call for Code & IBM

No current opportunities


West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)
West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)

Description: The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic.

Topics: Pediatric medical device development or adaptation to manage the impact of COVID-19 on children

Due Dates: Accepting applications on a rolling basis
Budget: $15,000


Robert Wood Johnson Foundation

No Current opportunities


Office of the Director of National Intelligence

No current opportunities


International Opportunities DEADLINE APPROACHING
Brazil

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro – FAPERJ

Emergency Action Projects to Combat the Effects of Covid-19 – FAPERJ / SES Partnership – 2020

Description: FAPERJ is providing funding to continue the work of networks in Brazil studying emerging and reemerging viruses and to finance the study of Covid-19 and the SARS-CoV-2 virus by various organizations, including startups and small, micro, and medium-sized companies based in the State of Rio de Janeiro.

Topics:

  • Genomics
  • Pathophysiology of the disease
  • Clinical aspects
  • Diagnosis of the disease
  • Epidemiology
  • Virus-host interaction
  • Development of diagnostic kits
  • Disease control and coping strategies
  • Innovative solutions to expand supplies of items such as masks, alcohol gel, and respirators

Due Dates: Applications are accepted on a rolling basis
Budget: Not specified

Finep

No current opportunities


Canada

Genome Canada

No current opportunities


National Research Council Canada

National Research Council Industrial Research Assistance Program (NRC IRAP)

Description: NRC Canada is offering project funding to small and medium-sized businesses that are working to provide COVID-19 solutions in the form of goods or services to health care workers and public health officials currently fighting the pandemic.

Topics: Development of COVID-19 solutions for health care workers and public health officials

Due Dates: None; applicants directly contact an Industrial Technology Advisor at NRC
Budget: Not specified


Eureka (Multiple Participating Nations)

No current opportunities


European Union

AMable/European Commission

AMable Open Call for Solution Ideas (COVID-19)

Description: AMable is seeking challenges related to COVID-19 and solutions that use additive manufacturing.

Topics: Challenges will involve a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality.

Due Dates: 10/1/2020
Budget: €10,000 per challenge


The European Commission

No current opportunities


France

DIM ELICIT

Special call for proposals: Development of innovative technologies & methods to fight SARS-CoV-2

Description: The DIM ELICIT organization would like to support collaborative projects developing innovative technologies and methods for the analysis, diagnosis and/or treatment of SARS-CoV-2. The program is open to research teams in the Ile de France region.

Topics: The technologies targeted in this call must belong to at least one core technology and one end-user application from the following lists:

Core technologies:

  • Microfludics
  • Biophotonic and waves
  • Image analysis and Big Data

End-user applications:

  • Single cell/Single molecule
  • Organ-on-a-chip
  • Technologies for in vivo biology
  • High-tech, low-cost technologies

Due Dates: Applications are accepted on a rolling basis
Budget: €15k for running and/or staff costs; €30k for equipment


Agence Nationale de la Recherche (ANR)

Research Action COVID-19 (RA-COVID-19)

Description: The ANR is launching a new call for Research-Action projects on COVID-19, focusing on WHO recommendations.

Topics:

  • Epidemiological studies
  • Physiopathogenesis of the disease
  • Infection prevention and control
  • Ethics and social dynamics
  • Global issues of the Covid-19 epidemic

Due Dates: 10/28/2020
Budget: €150,000


Korea

No current opportunities


Germany

Merck KGaA

Research Grant for Pandemic Preparedness

Description: Merck will consider proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Topics:

Pre-outbreak R&D Preparedness for pandemic disease:

  • Assessing the priority of pathogens and diseases with epidemic threat
  • Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats
  • Innovative technologies for better personal protection equipment for infection control

Response during outbreak:

  • Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation.
  • Fast-track identifying, testing and production of effective drugs and vaccines during outbreak

Due Dates: Applications will be reviewed on a rolling basis
Budget: €500,000 per year


Federal Ministry of Education and Research, Germany

No current opportunities


Global DEADLINE APPROACHING

Johnson & Johnson – JLABS DEADLINE APPROACHING

Johnson & Johnson Nurses Innovate QuickFire Challenge in COVID-19 Patient Care

Description: JLABS is looking for nurse-led ideas from nurses and nursing students around the world focused on improving COVID-19 patient care, with specific interest in, for example, facilitating remote patient monitoring and communications, data and reporting, resiliency and self-care, supporting a safe return to work or school, supporting sharing of best practices, and addressing racial disparities and inequities in healthcare.

Topics:

  • Treatment protocols
  • Health technologies
  • Medical devices
  • Treatment approaches
  • Consumer products
  • Community health approaches
  • Screening tools

Due Dates: 9/29/2020
Budget: $100,000


India

No current opportunities


Japan

No current opportunities


Malta

Malta Council for Science and Technology and Malta Enterprise Corporation

COVID-19 R&D Fund

Description: The Malta Council for Science and Technology and Malta Enterprise Corporation have announced a €5.3 Million COVID-19 R&D Fund targeting public, academic, and private entities to enable R&D on COVID-19. The fund is especially interested in projects with outcomes not only addressing innovative and/or improved approaches related to the current pandemic but also potential future waves and other antiviral relevant research.

Topics:

  • Relevant medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials
  • Medical devices, hospital and medical equipment (including ventilators and protective clothing and equipment as well as diagnostic tools) and necessary raw materials
  • Disinfectants and their intermediary products and raw chemical materials necessary for their production
  • Data collection and processing tools related to innovative and/or improved approaches with regards to current and/or future infectious disease prevention; o trajectory of the epidemic/pandemic disease
  • Better dissemination of recommendations by national (Public Health) and/or international health authorities (WHO)
  • Any other research related to infectious diseases that can lead to epidemics in humans

Due Dates: Applications are accepted on a rolling basis until 11/30/2020.
Budget: Not specified


Spain

Fundación MAPFRE (MAPFRE Foundation)

Ignacio H. de Larramendi Research Grants

Topics: The main topics are

  • Strategies for habit change: prevention of obesity and promotion of physical activity.
  • Patient education.
  • Physical injury assessment.
  • Health management: clinical quality and safety

However, special attention will be given to projects that incorporate aspects related to COVID-19, such as infection reduction, self-care and the culture of self-protection, the relationship between previous health status (lifestyle) and morbimortality, COVID-19 and mental health, etc

Due Date: 10/30/2020
Budget: 30,000 Euros


Ministry of Science and Innovation

Solicitud Urgente de Expresiones de Interés para la Financiación Extraordinaria de Proyectos de Investigación sobre el SARS-CoV-2 y la Enfermedad COVID-19 (Spanish)

Topics:

  • Scalable rapid diagnostic techniques for SARS-CoV-2, especially related to early stage detection and healthcare stratification
  • Clinical, biological, and molecular characteristics of COVID-19
  • Therapeutic development, including pharmaceutical and non-pharmaceutical measures
  • Antiviral resistance studies
  • Vaccine development
  • Socioeconomic impact of COVID-19
  • Integrated epidemiological controls, including AI and Big Data

Due Date: Ongoing
Budget: Not Specified; Total Program Budget €24,000,000


Sweden

No current opportunities


United Kingdom NEW!

Nesta NEW!

Collective Intelligence Grants – experiments for social impact

Description: Nesta, a UK-based foundation, wants to fund practical experiments that use novel combinations of AI and crowd intelligence to test innovative solutions that address pressing or emerging social and environmental issues related to the COVID-19 pandemic, such as reducing carbon emissions, preventing long-term unemployment, closing the school readiness and achievement gaps for disadvantaged children, and tackling health inequalities. This opportunity is open only to UK-based organizations.

Topics: Examples of topics include:

  • Reducing carbon emissions
  • Preventing long-term unemployment
  • Closing the school readiness and achievement gaps for disadvantaged children
  • Tackling health inequalities

Due Dates: Expressions of interest are due on 11/4/2020; chosen final applications are due 1/29/2020.
Budget: £30,000


Industrial Strategy Challenge Fund, Innovate UK

ISCF Transforming foundation industries: Building a resilient recovery

Description: The Industrial Strategy Challenge Fund and Innovate UK, part of UK Research and Innovation, has announced a grant program that will invest up to £8 million in innovation projects designed to support fast recovery and growth post-COVID-19. Innovations that improve the productivity and sustainability of the UK’s foundation industries, allowing them to remain globally competitive and become more environmentally sustainable, are the focus of this funding opportunity.

Topics: Proposals must focus on resource or energy efficiency opportunities through the development of:

  • long-term viability of domestic supply chains
  • new markets
  • new business models
  • new products and services
  • new processes

Projects must not focus on fuel switching or technologies for the capture of emissions, such as carbon capture and storage.

Due Date: 11/4/2020
Budget: £1 million


UK Research and Innovation (UKRI)

Proposals will be accepted from anyone who is normally eligible to apply for UKRI funding. You will need to show that you can start work within 4 weeks of the funding being confirmed.

View Solicitation

Topics: Short-term projects (12-18 months) addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

Due Date: Ongoing
Budget: 80% of the full economic cost


COVID-19 Rapid Response Rolling Call

Description: UKRI has announced a call for proposals for UK-led academic, small and medium-sized enterprise, and wider industry research that will address a wide range of COVID-19 knowledge gaps/needs, and which will lead to a benefit in UK, potentially international, public health within 12 months.

Topics:

  • Virology, immunity and pathophysiology
  • Diagnostics
  • Epidemiology
  • Personal protective equipment
  • Infection prevention and control measures
  • Public Health, Media and Communication
  • Clinical Management
  • Primary, Adjunctive and Supportive Therapies
  • Vaccines
  • Health and care delivery
  • Assays and animal models
  • Research infrastructure

Due Dates: Applications are accepted and reviewed on a rolling basis until 4/1/2021
Budget: Not limited, but must reflect the needs of the research project


Get funding for ideas that address COVID-19

Description: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural, and environmental impacts of the COVID-19 outbreak. 

Topics: An extensive list of research questions can be found at https://www.ukri.org/files/research-questions-for-covid-19/. These questions focus on various areas, including:

  • COVID-19 treatments
  • Contact tracing
  • Epidemiology
  • Data availability and use
  • Modeling and prediction
  • Accelerated use of AI and automation
  • National security and geopolitics
  • Engineering
  • Inequalities
  • Behavioral insights

Due Dates: None. Applications are accepted on a rolling basis.
Budget: Not specified